Milvexian
Sponsors
Janssen Pharmaceutica N.V., Belgium, Janssen Research & Development, LLC, Janssen Cilag International NV
Conditions
Acute Coronary SyndromeAtrial FibrillationCardiologyHealthyHealthy FemaleIschemic Stroke; Ischemic Attack, Transient
Phase 1
A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants
CompletedNCT04388501
Start: 2021-06-07End: 2021-10-27Updated: 2025-03-30
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
CompletedNCT04543383
Start: 2020-07-27End: 2023-06-09Updated: 2025-08-15
A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
CompletedNCT04844424
Start: 2021-04-14End: 2022-07-12Updated: 2025-05-23
A Study of Milvexian in Healthy Adult Females
CompletedNCT05706753
Start: 2023-01-25End: 2023-07-20Updated: 2025-03-30
Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
RecruitingNCT05702034
Start: 2023-02-15End: 2026-12-09Target: 15000Updated: 2026-03-13
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
CompletedNCT05754957
Start: 2023-04-07End: 2026-02-06Updated: 2026-03-27
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Active, not recruitingNCT05757869
Start: 2023-04-11End: 2026-10-31Updated: 2026-03-13
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
RecruitingPACTR202312651823009
Start: 2023-03-08Target: 16000Updated: 2026-01-27